Balyasny Asset Management’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Balyasny Asset Management’s Portfolio KDNY Stock Details KDNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-605,294	Closed	-$23.3M	–	2877
2023 Q2	$23.3M	Buy	+605,294	New	+$15.5M	0.05%	479
2023 Q1	–	Sell	-90,140	Closed	-$2.36M	–	3326
2022 Q4	$2.36M	Sell	90,140 -190,147	-68%	-$4.21M	0.01%	1349
2022 Q3	$5.51M	Buy	+280,287	New	+$5.62M	0.02%	941
2018 Q4	–	Sell	-16,193	Closed	-$595K	–	1854
2018 Q3	$595K	Buy	16,193 +13,616	+528%	+$437K	﹤0.01%	1332
2018 Q2	$90K	Buy	+2,577	New	+$98.8K	﹤0.01%	1714
2017 Q2	–	Sell	-15,720	Closed	-$845K	–	1833
2017 Q1	$845K	Buy	+15,720	New	+$888K	﹤0.01%	1158

Balyasny Asset Management's KDNY Position: Q3 2023 in Review

Balyasny Asset Management sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q3 2023, closing a stake of 605,294 shares — an estimated $23.3M sold.

Balyasny Asset Management first reported a position in KDNY in Q1 2017 and held it in 6 quarters. The position peaked at $23.3M in Q2 2023. 2 funds tracked by Wall St. Rank hold KDNY as of Q3 2023.

Balyasny Asset Management reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Balyasny Asset Management sold 605,294 Chinook Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $23.3M.
Balyasny Asset Management first reported a position in Chinook Therapeutics, Inc. Common Stock in Q1 2017 and held it in 6 quarters.
Balyasny Asset Management's Chinook Therapeutics, Inc. Common Stock position peaked at $23.3M in Q2 2023.
2 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Balyasny Asset Management's 13F filing for Q3 2023, filed 14 Nov 2023.